small molecule

EPSOLAY

BENZOYL PEROXIDE

Loss of exclusivityMay 2041latest FDA-listed patent expiry
CompanyMayne PharmaSee this company's full patent-cliff portfolio

Drug detail

Brand nameEPSOLAY
Active ingredientBENZOYL PEROXIDE
Strength5%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusRX

Listed patents

PatentExpiresType
12257348May 2041product
11628155December 2040use U-3356
12295935December 2040use U-3356
11426378August 2040use U-3356
11986456February 2040use U-3947
11877997February 2040use U-3356
10933046February 2040product
10945987February 2040use U-3356
11865100February 2040use U-3357
11541026February 2040use U-3356
9687465November 2032product
9868103August 2028product
12350382February 2028product
12156946February 2028product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EPSOLAY patent cliff — loss of exclusivity May 2041 | CliffBio